HeyJaredMarissa Russo
- Indexed articles, last 90 days
- 6
- Latest publication
- Sep 30, 2026
- Outlet visibility, for Fierce Biotech
- Top 500K sites
- Earliest in this view
- Sep 25, 2026
Latest articles
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo (opens the original)
Read excerpt
Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling with both obesity or overweight and type 2 diabetes, topping its own triple-G drug candidate retatrutide in that traditionally tricky-to-treat population. At the highest dose, the cocktail of amylin receptor agonist eloralintide and Lilly's approved GIP/GLP-1 med Zepbound (tirzepatide) yielded average weight loss of 54.1-pounds at 48 weeks, with A1C-lowering benefits shown, t
Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial (opens the original)
Read excerpt
Merck & Co. has touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis suppurativa (HS). The study met its primary and secondary endpoints at week 16, informing phase 3 development for tulisokibart in HS, according to the company. The win was first announced in August during its second-quarter earnings update. “We are excited to expand the clinical data for tulisokibart beyond inflammatory bowel disease with these positive phase 2b results,”
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer (opens the original)
Read excerpt
Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell carcinoma (BCC). The phase 2b study met its primary endpoint of visual and pathological response at week 24, as well as safety and tolerability, with no serious adverse events. These results, presented today during the European Academy of Dermatology and Venereology (EADV) congress in Vienna, support the advancement of Highlight’s BO-112 to late-stage development for localized pri
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’ (opens the original)
Read excerpt
ai3Bio has emerged from stealth with $48 million in funding and a buzzing platform for targeting T cells in autoimmune disease. The Massachusetts-based biotech is the product of Corner Therapeutics’ autoimmune technology splitting off and merging with the University of Pittsburgh-backed Novasenta. The funding was led by UPMC Enterprises and Ziff Capital Partners. They backed the complementary and foundational technology innovations from both Corner and Novasenta, which were combined to create ai
Scynexis bags $214M BARDA contract for antifungal development (opens the original)
Read excerpt
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis with a $214 million contract for development of a treatment for invasive fungal infections. The non-dilutive funding includes an initial payment of nearly $18.5 million to support advancement of oral and intravenous antifungal candidate (SCY-247) into a phase 2 trial. The contract has the option for extension for up to ten years and up to $214 million in funding to Scynexis, according to the release. SCY-247
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Fierce Biotech, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.